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Engineering an L-cell line that expresses insulin under the control of the glucagon-like 
peptide-1 promoter for diabetes treatment. 
 
ABSTRACT 
Diabetes mellitus is a complicated disease with a pathophysiology that includes 
hyperinsulinemia, hyperglycemia and other metabolic impairments leading to many clinical 
complications. It is necessary to develop appropriate treatments to manage the disease and 
reduce possible acute and chronic side effects. The advent of gene therapy has generated 
excitement in the medical world for the possible application of gene therapy in the treatment 
of diabetes. The glucagon-like peptide-1 (GLP-1) promoter, which is recognised by gut L-
cells, is an appealing candidate for gene therapy purposes. The specific properties of L-cells 
suggest that L-cells and the GLP-1 promoter would be useful for diabetes therapy approaches. 
Results: In this study, L-cells were isolated from a primary intestinal cell line to create 
suitable target cells for insulin expression studies. The isolated cells displayed L-cell 
properties and were therefore used as an L-cell surrogate. Next, the isolated L-cells were 
transfected with the recombinant plasmid consisting of an insulin gene located downstream of 
the GLP-1 promoter. The secretion tests revealed that an increase in glucose concentration 
from 5 mM to 25 mM induced insulin gene expression in the L-cells by 2.7-fold. Furthermore, 
L-cells quickly responded to the glucose stimulation; the amount of insulin protein increased 
2-fold in the first 30 minutes and then reached a plateau after 90 minutes. Conclusion: Our 
data showed that L-cells efficiently produced the mature insulin protein. In addition, the 
insulin protein secretion was positively regulated with glucose induction. In conclusion, 
GLP-1 promoter and L-cell could be potential candidates for diabetes gene therapy agents. 
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